Cagrilintide in Combination: Semaglutide, Tirzepatide and Retatrutide Pairings

A new chapter in metabolic research

For the past decade, metabolic science has been shaped by the incretin peptides, a family that includes GLP-1 and GIP. Each new generation has engaged more receptors and delivered deeper results. Attention is now turning to a different partner altogether: amylin. Rather than replacing the incretins, amylin appears to complement them, and the most studied amylin analogue, cagrilintide, has become the common thread linking three of the most discussed combinations in the field.

The science of amylin

Amylin is a peptide released by the pancreas together with insulin after a meal. Its role is simple: it signals to the brain that enough has been eaten. Acting mainly in the brainstem, it brings a meal to a comfortable close and slows how quickly the stomach empties. Cagrilintide is a long-acting analogue of this natural signal, designed to activate both amylin receptors and the related calcitonin receptor with a profile suited to once-weekly dosing. What makes it interesting is what it adds to its partners. Semaglutide works through the GLP-1 receptor. Tirzepatide engages both GLP-1 and GIP receptors. Retatrutide goes further, activating GLP-1, GIP and glucagon receptors. Pairing any of them with cagrilintide brings a second, complementary pathway into play, and in the case of retatrutide, five receptor types are engaged at once. Researchers have started to describe this as a five-receptor approach to metabolic health.

Retatrutide and cagrilintide: the most striking early signal

In September 2026, Petersen and colleagues published the first dedicated study of this pairing in Nature Metabolism, giving both peptides daily to male rats with obesity induced by a high-fat diet. The combination produced greater, dose-dependent weight loss and lower food intake than either peptide alone at equivalent doses, and it outperformed the matched combinations of cagrilintide with semaglutide and with tirzepatide. Beyond weight, the animals showed meaningful improvements in cholesterol, triglycerides and insulin levels. The most notable finding was that eating less did not tell the whole story. Using pair feeding, in which control animals receive exactly the same amount of food, and weight matching, the authors showed that the enhanced weight loss cannot be explained by reduced food intake alone. Profiling of blood proteins and brain gene expression pointed instead to shifts in energy metabolism and in the neural circuits that regulate energy balance. These results come from short treatment periods in male animals with daily dosing, and they open a clear path for the next stage of research into dosing, durability and translation to people.

Tirzepatide and cagrilintide: an early benchmark

This pairing entered the scientific literature through the same 2026 Nature Metabolism study in obese rats, included as a matched-dose comparator, a reference point against which the retatrutide combination could be measured. That role makes it valuable in its own right. Because tirzepatide and cagrilintide influence appetite and gastric emptying through different receptors, the pairing is a natural candidate for future human studies, which will be able to define its precise contribution, optimal dosing and tolerability profile.

Semaglutide and cagrilintide: the most advanced pairing

Of the three combinations, this is the one with the deepest evidence, built on large randomised phase 3 trials in people. The landmark REDEFINE 1 study, published in the New England Journal of Medicine in 2025, followed 3,417 adults with obesity or overweight and no diabetes for 68 weeks. Participants received 2.4 mg of each peptide weekly, either peptide on its own, or placebo, all alongside lifestyle support. The combination achieved an average weight loss of 20.4 per cent. Semaglutide alone reached 14.9 per cent, cagrilintide alone 11.5 per cent, and placebo 3.0 per cent. In other words, cagrilintide added roughly 5.5 percentage points on top of semaglutide. As with other peptides in this class, the most frequent effects were digestive, including nausea, constipation and vomiting. They were reported by 79.6 per cent of participants on the combination compared with 39.9 per cent on placebo, and were mainly temporary and mild to moderate. Only 5.9 per cent of participants stopped treatment because of side effects, compared with 3.7 per cent on placebo. A companion study, REDEFINE 2, extended these findings to adults with type 2 diabetes, where the combination produced 13.7 per cent weight loss compared with 3.4 per cent for placebo at 68 weeks, together with improved glycaemic control.

Why the combinations work

The rationale is complementary biology. Cagrilintide brings amylin-receptor activity to semaglutide's GLP-1 activity, to tirzepatide's GLP-1 and GIP activity, or to retatrutide's GLP-1, GIP and glucagon activity. Because these are distinct receptor targets, combining them can deliver benefits that simply raising the dose of a single peptide may not reproduce. At the same time, their effects converge downstream, since both amylin and GLP-1 signalling act on satiety and gastric emptying. This shared ground explains why digestive effects are the most commonly reported, and why gradual dose escalation is the standard approach in clinical research.

A longevity medicine perspective

In preventive and longevity-focused research, the quality of metabolic change matters as much as its size. The goal is not simply a lower number on the scale, but a healthier body underneath it. That begins with body composition. Assessments such as DEXA or bioimpedance help confirm that fat is being lost while lean muscle is preserved, an outcome strongly supported by high-protein nutrition and regular resistance training. Metabolic markers such as HbA1c, fasting insulin and glucose reveal how insulin sensitivity is evolving, while ApoB, LDL cholesterol, triglycerides, blood pressure and resting heart rate offer a window into cardiovascular health. Liver enzymes and digestive comfort complete the picture. Wearable technology adds a continuous layer, since trends in resting heart rate, heart rate variability, sleep and activity provide personalised insight that periodic lab tests alone cannot capture. Together these measures turn metabolic research into a precise, data-driven practice, ideally guided by qualified medical oversight.

Looking ahead

Semaglutide and cagrilintide stand today as the most established pairing, with phase 3 human data showing around 20 per cent average weight loss. Retatrutide and cagrilintide show the most compelling early science, including metabolic effects that reach beyond appetite. Tirzepatide and cagrilintide provide a valuable benchmark for the next wave of studies. Taken together, these findings point to an exciting direction for metabolic research: thoughtfully combining complementary peptide pathways to achieve deeper, healthier and more personalised results. Human trials of the newer pairings will be the defining next chapter.

Important note

This article summarises published research for educational purposes and is not medical advice. Several of the compounds discussed are investigational and not approved medicines. Any treatment decision should be made with a qualified physician. Everything referenced here is intended for research use only.

Sources

Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393:635 to 647. doi:10.1056/NEJMoa2502081. Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide and Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med. 2025. doi:10.1056/NEJMoa2502082. Petersen J, Merrild C, Holm SK, et al. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nature Metabolism. 2026;8:2069 to 2083. doi:10.1038/s42255-026-01603-y.

Frequently asked